BACKGROUND
Hypertension (HT) is a common complication of anti-angiogenic therapy. Its incidence, treatment and complications are undefined.
PATIENTS AND METHODS
Retrospective review of patients treated with bevacizumab (BV) from 2003-5. Common toxicity criteria (CTC) for adverse events version 3.0 were used.
RESULTS
Fifty-five out of the 154 patients treated with BV (35%) experienced HT. El...
